1. Introduction {#sec1}
===============

Noncommunicable diseases (NCDs) such as cardiomyopathies, asthma, diabetes mellitus, and cancer are the most common causes of death globally, with a higher percentage of premature deaths happening in developing nations than in developed nations \[[@B1]\]. This highlights the crucial need for simple and effective preventive strategies and treatments to reduce the current inequities within and among countries. At least half of these NCDs-related deaths are caused by common risk factors including malnutrition, a condition that represents a critical public health concern \[[@B2], [@B3]\]. Malnutrition occurs when the nutritional needs for growth (protein and calories) are not met within the context of either undernutrition or overnutrition and lead to deficiencies of essential micronutrients, with detrimental and sometimes irreversible effects \[[@B4]\].

The use of alternative therapies, in the form of dietary supplements, is becoming very common throughout the world, as many people nowadays are adopting a variety of lifestyle habits that contribute to healthy living \[[@B5]\]. Dietary supplements comprise a wide range of products intended for ingestion to meet essential nutritional needs. They may be individual components or combinations of vitamins, minerals, amino acids, or herbal products and have intermediate form between foods and drugs \[[@B6]\]. Thus, they possess both food and drug characteristics, a number of them being more food-like or drug-like, depending on their nature.

Dietary supplements are essential when nutritional needs are not covered by diet alone; however, the use of dietary supplementation when nutritional sufficiency has already been achieved remains controversial, as possible toxic effects of excessive intake have been reported for some micronutrients such as *β*-carotene and vitamin E \[[@B7], [@B8]\]. Whereas the quest for improved health with dietary supplements is commendable, there is a paucity of scientific data on some of the purported therapeutic efficacies of these dietary supplements.

Dietary supplements, including those of herbal origin, are known to alter the pharmacokinetics of concomitantly administered conventional drugs \[[@B9]\]. These supplements (or their constituents) often induce or inhibit drug-metabolizing enzymes such as cytochrome P450 (CYP), which play significant roles in phase I biotransformation reactions, converting lipophilic agents into hydrophilic metabolites and thereby facilitating excretion \[[@B10]\]. A typical example of a dietary supplement (herb) that modulates the activities of CYP enzymes is St. John\'s wort*(Hypericum perforatum)* \[[@B11], [@B12]\].

A number of dietary supplements currently available on the market have been reported to replenish levels of reduced glutathione (GSH), the most abundant naturally occurring antioxidant in the body \[[@B13]\]. Despite a scarcity of available scientific evidence, these GSH-enhancer dietary supplements are purported to play a potential role in the prevention of NCDs, especially those mediated by free radicals and characterized by depleted stores of tissue GSH \[[@B14]\]. One of such supplements, CellGevity, contains the GSH-precursor molecule, riboceine (D-ribose-L-cysteine), which has been reported to effectively deliver cysteine into the cell and enhance GSH level \[[@B15]\]. Riboceine has been shown to be significantly more effective than other glutathione enhancers \[[@B16]\], hence, the rationale for the choice of this dietary supplement in the present study.

In addition to riboceine, CellGevity contains an amalgam of constituents comprising turmeric root extract (curcumin), resveratrol, aloe extract, milk thistle, quercetin, broccoli seed extract, alpha lipoic acid, grape seed extract, vitamin C, selenomethionine, cordyceps, and piperine. Some of these constituents are known as inducers and/or inhibitors of CYP enzymes. Curcumin and resveratrol, for example, are potent inhibitors of CYP enzymes \[[@B17]--[@B19]\], while*aloe vera* induces CYP reductase and some Phase II enzymes \[[@B20]\].

Given the reported cases of induction and/or inhibition of CYP enzymes by some of its constituents and the potential supplement-drug interaction that may ensue, the present study investigates the effect of CellGevity dietary supplement on the activities of selected rat liver microsomal CYP enzymes and evaluates its total antioxidant potential.

2. Materials and Methods {#sec2}
========================

*Ethical Statement*. All animal work was conducted according to the guidelines of the National Institute of Health for the Care of Laboratory Animals \[[@B21]\] and was approved by the Scientific and Technical Committee of Noguchi Memorial Institute for Medical Research, University of Ghana.

*Experimental Animals*. Prior to experiment, 20 male Sprague Dawley rats weighing 300 ± 50 g (≥8 weeks old) from the Animal Experimentation Unit, Center for Plant Medicine Research, Mampong-Akuapem, Ghana, were fed ad libitum using standard animal lab pellet (Sankofa Flour and Feeds, Accra, Ghana) and were housed in 4 groups of 5 animals per cage under standard laboratory conditions (25 ± 1°C ambient temperature, 60--70% relative humidity, and 12:12 h light : dark cycle) to acclimatize to the laboratory condition for 7 days.

*Treatment Groups*. Following acclimatization, rats were randomly assigned to one of the four experimental groups, being low dose supplement treatment (LDT; *n* = 5), high dose supplement treatment (HDT; *n* = 5), positive control (PC; *n* = 5), and negative control (NC; *n* = 5). The LDT group received a daily dose of 4 mg/kg of the supplement while the HDT group received 8 mg/kg. The PC group received a daily administration of 80 mg/kg of phenobarbitone, whereas the NC group was given distilled water daily. Each group received their respective treatment via oral route for 7 days. Following 7 days of treatment, animals were sacrificed by injection of an overdose of sodium pentobarbital intraperitoneally, and liver samples were harvested and snap-frozen in liquid nitrogen and stored at −80°C until further analysis.

2.1. Antioxidant Assays {#sec2.1}
-----------------------

*2,2-Diphenyl-2-Picryl-Hydrazyl (DPPH) Assay*. The DPPH method used was a modification of one reported by Blois \[[@B22]\]. Briefly, 20 mg of the supplement (CellGevity powder; Max International, Ghana) was dissolved in 1.0 ml of dimethyl sulfoxide (DMSO; Sigma Aldrich, USA) to obtain a stock solution of 20 mg/ml. Twofold serial dilutions of the stock were made to obtain concentrations of 10, 5, 2.5, 1.25, 0.625, and 0.3125 mg/ml. Twofold serial dilutions of the positive control, butylated hydroxyl toluene (BHT; St. Louis, MO, USA), were made to obtain concentrations of 0.5, 0.25, 0.125, 0.0625, 0.03125, and 0.015625 mg/ml. One hundred microliters of each of the samples and BHT dilutions was pipetted separately in triplicate into 96-well plates. A volume of 100 *μ*L of 0.5 mM DPPH solution (Steinheim, Germany) was then added to each of the wells to obtain a total volume of 200 *μ*L. The plates were incubated in the dark at room temperature for 20 minutes and absorbance was read at a wavelength of 517 nm.

*Total Phenolic Assay*. The assay used to estimate total phenols in the supplement was a modification of one reported by Marinova et al. \[[@B23]\]. Briefly, a stock solution of the supplement was prepared by dissolving 20 mg of the sample in 1.0 ml of DMSO. Twofold serial dilutions of this stock were made to obtain concentrations of 10.0, 5.0, 2.5, and 1.25 mg/ml. The standard was prepared by dissolving 1.0 mg of gallic acid (generously provided by the Department of Nutrition and Food Science, University of Ghana) in 10% absolute ethanol. Twofold serial dilutions were made to obtain concentrations of 0.5, 0.25, 0.125, 0.0625, 0.03125, and 0.015625 mg/ml. One hundred microliters of each of the sample dilutions and the standard was pipetted separately in triplicate into 96-well plates. A volume of 100 *μ*L of Folin-Ciocalteu reagent (Buchs, Switzerland) was then added to each well followed by 200 *μ*L of sodium bicarbonate solution (0.2 g/ml) to obtain a total volume of 400 *μ*L. The plates were incubated at room temperature for 120 minutes and absorbance read at a wavelength of 650 nm.

*Total Flavonoid Assay*. The total flavonoid assay used was one adapted from Ordoñez et al. \[[@B24]\]. Briefly, a stock solution of the supplement was prepared and diluted to obtain concentrations of 10.0, 5.0, 2.5, and 1.25 mg/ml. Quercetin standard (Buchs, Switzerland) was prepared and diluted to obtain concentrations of 0.1, 0.05, 0.025, 0.0125, 0.00625, 0.003125, and 0.0015625 mg/ml. One hundred microliters of each of the sample dilutions and the standard was pipetted separately in triplicate into 96-well plates. A volume of 100 *μ*L of aluminum chloride solution (2% w/v; Sigma Aldrich, USA) was added to each of the wells to obtain a final volume of 200 *μ*L per well. The plates were then incubated at room temperature for 20 minutes after which absorbance was read at a wavelength of 415 nm.

2.2. Rat Liver CYP Enzyme Induction/Inhibition Assays {#sec2.2}
-----------------------------------------------------

*Preparation of Microsomal Fractions and Protein Level Determination*. Liver samples weighing 7.82 g were homogenized separately with two volumes of potassium phosphate buffer (pH 7.4) in a mortar with pestle. The homogenate was centrifuged at 4,500 rpm for 20 minutes at 4°C and the supernatant collected. Next, the supernatant was further centrifuged at 40,000 rpm for 60 minutes at 4°C with an ultra-centrifuge (Beckman Avanti J-25, USA). Following ultra-centrifugation, the resultant supernatant (cytosol) was separated from the pellet (microsomes). The microsomes obtained were then homogenized in potassium phosphate buffer (pH 7.4) to form a solution. Fourfold serial dilutions were carried out on the microsomal solutions using potassium phosphate buffer. Serial dilutions (2-fold, 6 dilutions) were also made with a protein standard, bovine serum albumin (BSA; St. Louis, MO, USA). Ten microliters of the BSA and 200 *μ*L of Biorad reagent (Bio-Rad Laboratories Inc., USA) was added to each microsomal dilution in a 96-well plate and incubated at room temperature for 5 minutes, and absorbance was read at a wavelength of 590 nm.

*CYP1A1/1A2-Ethoxyresorufin O-Deethylase (EROD), CYP1A2-Methoxyresorufin O-Demethylase (MROD), CYP3A4-BenzyloxyresorufinO-Debenzylase (BROD), and CYP2B1/2B2-Pentoxyresorufin O-Depentylase (PROD) Assays*. Inhibition of CYP 1A1/1A2, 1A2, 3A4, and 2B1/2B2 enzymes by the supplement was determined using fluorimetric assays similar to ones described by Appiah-Opong et al. \[[@B17]\] and Umegaki et al. \[[@B26]\] but with slight modification. Briefly, 70 *μ*L of potassium phosphate buffer (pH 7.4) was pipetted in triplicate into a 96-well plate followed by addition of 10 *μ*L of each substrate (ethoxyresorufin, methoxyresorufin, benzyloxyresorufin, and pentoxyresorufin purchased from St. Louis, MO, USA). Next, 10 *μ*L of the rat liver microsomal fraction obtained from each treatment group was added and incubated at 37°C for 5 min. Ten microliters (100 *μ*M) of nicotinamide adenine dinucleotide phosphate (NADPH; St. Louis, MO, USA) was added to each of the wells and incubated at 37°C for 10, 20, and 30 min (for CYPs 1A1/1A2 and 1A2, 2B1/2B2 and 3A4, respectively). A volume of 40 *μ*L of stopping solution (20% 0.5 M Tris and 80% acetonitrile) was added and the plate gently was shaken. Fluorescence was read at specific wavelengths at 586 nm.

*CYP2D6-Dextromethorphan O-Demethylation Assay*. The effect of the supplement on dextromethorphan O-demethylation by CYP2D6 was assayed as described by Appiah-Opong et al. \[[@B17]\]. Briefly, 350 *μ*L of potassium phosphate buffer (pH 7.4) was pipetted into Eppendorf tubes in triplicate. Fifty microliters of 0.25 mM dextromethorphan (Milan, Italy) was added followed by 50 *μ*L of microsomes obtained from each group. Preincubation was done at 37°C for 5 minutes in a water bath after which 50 *μ*L of NADPH solution (100 *μ*M) was added. Further incubation was done for 45 minutes, followed by the addition of 100 *μ*L of stopping solution (300 mM zinc sulphate heptahydrate). The mixture was centrifuged at 4,000 rpm for 15 min at room temperature, and the supernatant was collected in vials and analyzed using an isocratic HPLC method with a C18 column (150 mm × 4.6 mm, VP-ODS). The mobile phase consisted of 24% (v/v) acetonitrile and 0.1% (v/v) trimethylamine adjusted to pH 3.0 with perchloric acid. The carrier flow rate was 0.8 ml/min and peaks were monitored at wavelengths of 280 nm (excitation) and 310 nm (emission).

*CYP2C9-Diclofenac Hydroxylation Assay*. The effect of the supplement on hydroxylation of diclofenac to 4-hydroxydiclofenac by CYP2C9 was determined as described by Appiah-Opong et al. \[[@B27]\]. Briefly, 350 *μ*L of potassium phosphate buffer (pH 7.4) was pipetted into Eppendorf tubes followed by 50 *μ*L of 0.05 mM diclofenac (Overrijse, Belgium). Next, 50 *μ*L of the microsomal fraction obtained from each treatment group was added (in triplicate) and preincubated at 37°C for 5 minutes in a water bath. A volume of 50 *μ*L of NADPH solution (100 *μ*M) was added to each tube and further incubated in the water bath at 37°C for 10 minutes. The reaction was terminated by addition of 200 *μ*L of stopping solution (ice-cold methanol) and the mixture was centrifuged at 12,000 rpm for 8 minutes at room temperature. The supernatants were collected in vials and analyzed using high-performance liquid chromatography (HPLC) \[Agilent 1100 Series, Germany\]. The HPLC conditions for the assay comprised an injection volume of 50 *μ*L, a flow rate of 0.8 ml/min, a C18 column (150 mm × 4.6 mm, VP-ODS), a temperature of 40°C, and a maximum pressure of 40 bar. A diode array served as the detector. Products formed were measured using an isocratic HPLC method. The mobile phase consisted of 60% of 20 mM potassium phosphate buffer (pH 7.4), 22.5% methanol, and 17.5% acetonitrile.

2.3. Statistical Analysis {#sec2.3}
-------------------------

All values are expressed as mean ± standard deviation (SD). Differences between groups were tested for significance using a One-Way ANOVA. *p* values \< 0.05 were considered statistically significant. Significant differences were calculated with Bonferroni\'s Multiple Comparison Tests, and graphs were produced using Graph Pad Prism Software Version 7 (GraphPad Software, Inc., USA).

3. Results {#sec3}
==========

3.1. Antioxidant Assays {#sec3.1}
-----------------------

To evaluate the antioxidant potential of CellGevity dietary supplement, DPPH, total phenolic, and flavonoid assays were used. The concentration of the supplement required to inhibit 50% of free radicals (IC~50~) was 0.34 ± 0.07 mg/ml compared to 0.076 ± 0.03 mg/ml of the BHT (positive control). The total phenolic content of the supplement at a concentration of 2.5 mg/ml was 34.97 g gallic acid equivalent (GAE)/100 g while its total flavonoid content at a concentration of 2.5 mg/ml was 6 g quercetin equivalent (QE)/100 g. Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"} show the IC~50~ values of CellGevity as compared to BHT.

3.2. CYP Enzyme Assays {#sec3.2}
----------------------

In order to determine the effect of CellGevity dietary supplement on rat liver microsomal cytochrome P450 (CYP) enzyme activities, selected CYP assays were used.

*CYP1A1/1A2 and CYP1A2 Assays*. There was no significant difference in the activity of CYP1A1/1A2 enzyme among NC, LDT, and HDT groups ([Figure 2(a)](#fig2){ref-type="fig"}; *p* \> 0.05). However, the CYP1A1/1A2 enzyme activity of these three groups markedly decreased compared to PC group ([Figure 2(a)](#fig2){ref-type="fig"}; *p* \< 0.05). A similar observation was made in CYP1A2 enzyme activity ([Figure 2(b)](#fig2){ref-type="fig"}).

*CYP2B1/2B2 and CYP3A4 Assays*. Unlike CYP1A1/1A2 and CYP1A2 enzyme activities, which showed no significant difference between NC, LDT, and HDT groups in the microsomal fractions, the activity of the CYP2B1/2B2 enzyme in LDT and HDT groups markedly decreased compared to NC group ([Figure 2(c)](#fig2){ref-type="fig"}; *p* \< 0.001). A similar pattern was observed in [Figure 2(d)](#fig2){ref-type="fig"}. However, whereas the PC group showed markedly reduced CYP2B1/2B2 enzyme activity compared to NC group in [Figure 2(c)](#fig2){ref-type="fig"} (*p* \< 0.05), that in CYP3A4 in [Figure 2(d)](#fig2){ref-type="fig"} showed no difference in comparison with the NC group (*p* \> 0.05).

*CYP2D6 and CYP2C9 Assays*. CYP2D6 enzyme activity in LDT group increased significantly compared to HDT group ([Figure 2(e)](#fig2){ref-type="fig"}; *p* \< 0.05). In addition, NC group showed a markedly high CYP2D6 activity in comparison with PC group ([Figure 2(e)](#fig2){ref-type="fig"}; *p* \< 0.001). As seen in [Figure 2(b)](#fig2){ref-type="fig"}, the activity of CYP2C9 followed a similar pattern in which no significant difference was observed between LDT and HDT groups while activity in NC group also markedly decreased ([Figure 2(f)](#fig2){ref-type="fig"}; *p* \< 0.05).

*Overall Effect of the Supplement on Rat CYP Enzymes*. The overall effect of this supplement on selected CYP enzymes is summarized in [Table 1](#tab1){ref-type="table"}. Inhibition of CYP enzyme activity by the supplement was not dose-dependent. The general trend of enzyme inhibition (highest to lowest) by both doses of the supplement was CYP2B1 \> CYP3A4 \> CYP2C9 \> CYP1A1/1A2 \> CYP1A2 \> CYP2D6.

4. Discussion {#sec4}
=============

In the current study, we evaluated the antioxidant potential of CellGevity dietary supplement, comprising an aggregate of ingredients, and the effect of this supplement on the activities of selected rat liver microsomal enzymes. This study focuses on CYP enzymes (one of the conserved entities among species) which are the main enzymes involved in numerous oxidative reactions and often play a critical role in the metabolism and pharmacokinetics of xenobiotics. It is well established that some rat CYP enzymes are closely related to those of humans. For example, CYP1A shows a strong conservation among species with an identity to human \> 80% in rat (83 and 80%, respectively, for CYP1A1 and -1A2) \[[@B28], [@B29]\].

Some constituents of CellGevity dietary supplement, such as curcumin, resveratrol, milk thistle, quercetin, and piperine, are known inhibitors of CYP3A4 \[[@B17]--[@B19], [@B30]--[@B32]\]. Hence, it is not surprising that this isoform was one of the enzymes significantly inhibited by the dietary supplement. CYP3A4 is one the most abundant CYP isoforms in human liver and is involved in the biotransformation of the majority of drugs \[[@B33]\]. However, some discrepancies between rats and human CYP3A4 isoforms, in the metabolism of drugs such as dihydropyridine calcium-channel blockers (e.g., nifedipine), have been reported, probably suggesting that rat is not a good model to study CYP3A4 induction \[[@B29], [@B34], [@B35]\]. Therefore, data from the current study, suggesting that CellGevity dietary supplement could alter the metabolism of some drugs that serve as human CYP3A4 substrates, should be interpreted cautiously.

Our study also showed that CellGevity dietary supplement significantly inhibited rat CYP2B1/2B2. Curcumin, one of the constituents of the supplement, is a less potent inhibitor of rat CYP2B1/2B2 compared to CYP1A1/1A2 enzyme \[[@B36]\]. This earlier report contradicts our finding, as we observed a significant inhibitory effect of the dietary supplement on CYP2B1/2B2 enzyme activity but not on the activities of CYP1A1/1A2 and CYP1A2 enzymes. As the dietary supplement has several constituents that affect CYP enzyme activity, it is possible that these refuting observations could be due to the synergistic inhibitory action of other constituents on CYP2B1/2B2 activity besides curcumin. It is important to note that the CYP2B subfamily is more abundant in rodents than in humans. In humans, however, the orthologous form of CYP2B1/2B2 is CYP2B6 \[[@B37]\]. Appiah-Opong et al. \[[@B17]\] reported that curcumin inhibited the human CYP2B6 enzyme, which is consistent with our observation in rats. This inhibitory effect on CYP2B activity suggests potential interaction when CellGevity dietary supplement is coadministered with drugs metabolized by this subfamily of CYP enzymes.

Another CYP enzyme, significantly inhibited by CellGevity dietary supplement, was CYP2C9. Although the effect of individual constituents of this dietary supplement on CYP enzyme activity was not investigated in our study, rodent and human microsome studies have shown that resveratrol, a constituent of this dietary supplement, is a potent inhibitor of CYP2C9 \[[@B38], [@B39]\]. A diet containing 0.5% w/w resveratrol fed to mice for 12 weeks was found to enhance the anticoagulant activity of warfarin, suggesting possible inhibition of CYP2C9 \[[@B38]\]. Using losartan as a probe drug, a daily dose of 1.0 g of resveratrol administered for 4 weeks was found to inhibit human CYP2C9 by 2.71‐fold \[[@B39]\]. Previous reports also suggest that curcumin is a potent inhibitor of human recombinant CYP2C9 \[[@B17]\]. Additionally, two flavonolignans from milk thistle (another constituent of this dietary supplement) were found to inhibit human CYP2C9-mediated warfarin metabolism \[[@B40]\]. These pieces of evidence suggest that CellGevity dietary supplement could modulate human CYP2C9 enzyme activity.

In the current study, the EC~50~ value of CellGevity dietary supplement was 0.34 ± 0.07 mg/ml compared to 0.076 ± 0.03 mg/ml of the BHT. The total phenolic content of the supplement at a concentration of 2.5 mg/ml was 34.97 g gallic acid equivalent (GAE)/100 g while its total flavonoid content at a concentration of 2.5 mg/ml was 6 g quercetin equivalent (QE)/100 g. This antioxidant potential is moderately high compared to a related study where the authors reported a synergistic antioxidant activity of a green tea of herbal origin determined by an EC~50~ value of 33.5 mg/ml, a total phenolic, and flavonoid content of 2.5 g GAE/10 g and 1.2 g QE/10 g, respectively \[[@B41]\]. Furthermore, there have been studies including ours in which authors reported antioxidant potential of dietary supplements using*in vitro* assays \[[@B42]\]. However, a constituent of CellGevity dietary supplement, riboceine, is a prodrug which requires bioactivation*in vivo*. Once in circulation, riboceine is metabolized into cysteine and ribose, which are transported into cells \[[@B15]\]. It is noteworthy that cysteine is a substrate for GSH synthesis in the liver and other organs \[[@B43]\], suggesting that CellGevity dietary supplement activates GSH pathway and possibly other endogenous antioxidants pathways, thereby bolstering the endogenous antioxidant defense system.

5. Conclusion {#sec5}
=============

In conclusion, this study reports that CellGevity dietary supplement possesses antioxidant property*in vitro* and also inhibits activities of rat liver CYP2B1, CYP3A4, and CYP2C9 enzymes. Inhibition of these selected CYP enzymes by this dietary supplement suggests the possibility that CellGevity dietary supplement may contribute to supplement (herb-) drug interactions in humans.
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![Concentration-response curves showing IC~50~ values for butylated hydroxytoluene (BHT; positive control (a)) and CellGevity dietary supplement (b).](ECAM2018-7462839.001){#fig1}

![(a)*Effect of CellGevity dietary supplement on CYP1A1/1A2 activity in rat liver microsomes*. Negative control (NC; distilled water), positive control (PC; phenobarbitone 80 mg/kg), low dose treatment (LDT; 4 mg/kg supplement), and high dose treatment (HDT; 8 mg/kg supplement). Data represent mean ± standard deviations. *∗* and *∗∗* are values statistically different as indicated with *p* \< 0.05 and *p* \< 0.001, respectively. (b)*Effect of CellGevity dietary supplement on CYP1A2 activity in rat liver microsomes*. Negative control (NC; distilled water), positive control (PC; phenobarbitone 80 mg/kg), low dose treatment (LDT; 4 mg/kg supplement), and high dose treatment (HDT; 8 mg/kg supplement). Data represent mean ± standard deviations. *∗* and *∗∗* are values statistically different as indicated with *p* \< 0.05 and *p* \< 0.001, respectively. (c)*Effect of CellGevity dietary supplement on CYP2B1/2B2 activity in rat liver microsomes*. Negative control (NC; distilled water), positive control (PC; phenobarbitone 80 mg/kg), low dose treatment (LDT; 4 mg/kg supplement), and high dose treatment groups (HDT; 8 mg/kg supplement). Data represent mean ± standard deviations. *∗* and *∗∗* are values statistically different as indicated with *p* \< 0.05 and *p* \< 0.001, respectively. (d)*Effect of CellGevity dietary supplement on CYP3A4 activity in rat liver microsomes*. Negative control (NC; distilled water), positive control (PC; phenobarbitone 80 mg/kg), low dose treatment (LDT, 4 mg/kg supplement), and high dose treatment (HDT; 8 mg/kg supplement). Data represent mean ± standard deviations. *∗* and *∗∗* are values statistically different as indicated with *p* \< 0.05 and *p* \< 0.001, respectively. (e)*Effect of CellGevity dietary supplement on CYP2D6 activity in rat liver microsomes*. Negative control (NC; distilled water), positive control (PC; phenobarbitone 80 mg/kg), low dose treatment (LDT, 4 mg/kg supplement), and high dose treatment (HDT; 8 mg/kg supplement). Data represent mean ± standard deviations. *∗* and *∗∗* are values statistically different as indicated with *p* \< 0.05 and *p* \< 0.001, respectively. (f)*Effect of CellGevity dietary supplement on CYP2C9 in rat liver microsome*. Negative control (NC; distilled water), positive control (PC; phenobarbitone 80 mg/kg), low dose treatment (LDT, 4 mg/kg supplement), and high dose treatment (HDT; 8 mg/kg supplement). Charts represent mean ± standard deviations. *∗* are values statistically different as indicated with *p* \< 0.05.](ECAM2018-7462839.002){#fig2}

###### 

A summary of the effect of the supplement on rat CYP enzymes.

  CYP isoform   Assay                              Effect of supplement on CYP activity
  ------------- ---------------------------------- -------------------------------------------------------------------------------
  CYP 1A1/1A2   EROD                               No significant decrease in enzyme activity
  CYP 1A2       MROD                               No significant decrease in enzyme activity
  CYP 2B1/2B2   PROD                               Significant decrease in enzyme activity (*p* \< 0.001; LDT and HDT)
  CYP 2C9       Diclofenac hydroxylation           Significant decrease in enzyme activity (*p* \< 0.05; LDT)
  CYP 2D6       Dextromethorphan O-demethylation   No significant decrease in enzyme activity
  CYP 3A4       BROD                               Significant decrease in enzyme activity (LDT: *p* \< 0.001; HDT: *p* \< 0.05)
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